Pacific Biosciences of California Inc reports results for the quarter ended December 31 - Earnings Summary

• Pacific Biosciences of California Inc PACB.OQ reported quarterly adjusted earnings of 51 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -29 cents to -16 cents per share.

• Revenue fell 32.8% to $39.22 million from a year ago; analysts expected $40.16 million.

• Pacific Biosciences of California Inc's reported EPS for the quarter was 1 cent​.

• The company reported quarterly net income of $3.57 million.

• Pacific Biosciences of California Inc shares had fallen by 25.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.50

This summary was machine generated from LSEG data February 13 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)